AstraZeneca PLC
AZN79.560USD
Today
-1.90%
5 Days
-2.62%
1 Month
+1.39%
6 Months
+2.53%
Year to Date
+21.43%
1 Year
+1.65%
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
Score Analysis
Analyst Rating
Company Highlights
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology firm headquartered at the Cambridge Biomedical Campus in Cambridge, UK. The company boasts a diverse portfolio of products aimed at treating major diseases in areas such as oncology, cardiovascular health, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.
Founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group, it includes offerings for both primary and specialty care, coverage for rare diseases, and maintains a strong global presence across various regions. Since the merger, AstraZeneca has consistently ranked among the largest pharmaceutical companies worldwide and has executed numerous corporate acquisitions, such as Cambridge Antibody Technology, MedImmune, Spirogen, and Definiens. Its research and development efforts are concentrated in three strategic centers: Cambridge in the UK, Gothenburg in Sweden, and Gaithersburg in Maryland, US.
AstraZeneca’s corporate lineage can be traced back to 1913, when Astra AB was established by a significant group of physicians and pharmacists in Södertälje. Throughout the 20th century, Astra AB evolved into Sweden's largest pharmaceutical company. Its British counterpart, Zeneca PLC, was created in 1993 when ICI divested its pharmaceuticals division; six years later, Astra AB and Zeneca PLC merged, designating the United Kingdom as the headquarters.
AstraZeneca's primary listing is on the London Stock Exchange, where it is part of the FTSE 100 Index, alongside a secondary listing on Nasdaq Stockholm. It is also traded on the American Nasdaq and is included in the Nasdaq-100 index. AstraZeneca ranks among the pharmaceutical companies globally with one of the highest market capitalizations.
News
George Soros Q2 2025 13F Report: Tactical Bets and Market Mastery Unveiled
TradingKey - George Soros, the iconic financier and chairman of Soros Fund Management, remains a defining figure in global investing. Widely recognized for his theory of market reflexivity, which contends that investor biases and market fundamentals form feedback loops influencing asset prices
Trump Strikes Again: Sends Warning Letter to Eli Lilly and Others, Drug Pricing Back in the Spotlight
TradingKey - On Thursday Eastern Time, U.S. President Donald Trump renewed pressure on the pharmaceutical industry by sending formal letters to several major drugmakers
George Soros’s Playbook in 2025: Opportunistic, Nimble, and Undeniably Contrarian
TradingKey - When ordinary investors hear George Soros's name, it evokes that hedge fund legend who “broke the Bank of England,” but today Soros Fund Management trades with a system that is far more complicated than speculating in currencies.
AstraZeneca breast cancer drug shows positive results, shares up
Investing.com -- AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the illness during a late-stage clinical trial.
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
Feb 20 (Reuters) - AstraZeneca AZN.L will buy longtime partner FibroGen's FGEN.O China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's second-biggest economy.
Financial Indicators
EPS
Total revenue
Company
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology firm headquartered at the Cambridge Biomedical Campus in Cambridge, UK. The company boasts a diverse portfolio of products aimed at treating major diseases in areas such as oncology, cardiovascular health, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.
Founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group, it includes offerings for both primary and specialty care, coverage for rare diseases, and maintains a strong global presence across various regions. Since the merger, AstraZeneca has consistently ranked among the largest pharmaceutical companies worldwide and has executed numerous corporate acquisitions, such as Cambridge Antibody Technology, MedImmune, Spirogen, and Definiens. Its research and development efforts are concentrated in three strategic centers: Cambridge in the UK, Gothenburg in Sweden, and Gaithersburg in Maryland, US.
AstraZeneca’s corporate lineage can be traced back to 1913, when Astra AB was established by a significant group of physicians and pharmacists in Södertälje. Throughout the 20th century, Astra AB evolved into Sweden's largest pharmaceutical company. Its British counterpart, Zeneca PLC, was created in 1993 when ICI divested its pharmaceuticals division; six years later, Astra AB and Zeneca PLC merged, designating the United Kingdom as the headquarters.
AstraZeneca's primary listing is on the London Stock Exchange, where it is part of the FTSE 100 Index, alongside a secondary listing on Nasdaq Stockholm. It is also traded on the American Nasdaq and is included in the Nasdaq-100 index. AstraZeneca ranks among the pharmaceutical companies globally with one of the highest market capitalizations.
Related Instruments
